In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.
about
Pharmacokinetics of sarafloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications.In vivo efficacies of levofloxacin and ciprofloxacin in acute murine hematogenous pyelonephritis induced by methicillin-susceptible and-resistant Staphylococcus aureus strainsIn vitro and in vivo activities of Q-35, a new fluoroquinolone, against Mycoplasma pneumoniae.A-61827 (A-60969), a new fluoronaphthyridine with activity against both aerobic and anaerobic bacteria.Activity of E-3846, a new fluoroquinolone, in vitro and in experimental cystitis and pyelonephritis in rats.Comparative antibacterial activities of temafloxacin hydrochloride (A-62254) and two reference fluoroquinolones.In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones.In vitro activity of A-56619 (difloxacin), A-56620, and other new quinolone antimicrobial agents against genital pathogens.Effects of new quinolones on Mycoplasma pneumoniae-infected hamsters.Activity of temafloxacin against respiratory pathogens.Mode of action, and in vitro and in vivo activities of the fluoroquinolones.Therapeutic evaluation of difloxacin (A-56619) and A-56620 for experimentally induced Bacteroides fragilis-associated intra-abdominal abscess.Difloxacin metabolism and pharmacokinetics in humans after single oral dosesAryl-fluoroquinolone derivatives A-56619 (difloxacin) and A-56620 inhibit mitogen-induced human mononuclear cell proliferation.Pharmacokinetics of difloxacin in olive flounder Paralichthys olivaceus at two water temperatures.Pharmacokinetics of difloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications.Macrolides: problems and promises.
P2860
Q23913397-B4D47A63-47FA-4BDB-9972-DCEA287E55F4Q28379294-8BD6769B-3E41-423F-949F-5660E720A8D5Q34728521-79FFDE29-6E83-4F2B-84B4-8D90E93EFF8BQ35288155-A0ACF1A1-3A9D-4BD8-9C68-C9C32520F78CQ35303163-2382703A-56CB-46A7-AFDB-029126D79420Q35543422-86D97BE3-F20F-4C9B-A41E-FDBF1483E7F0Q35564364-9A838794-B734-450B-8AB2-38D6E77E6FF0Q35653982-D4A1F785-F6E4-4F6E-B344-892DDA94C2B4Q35808771-03C3A51C-8961-477E-9BB9-42BC0898D744Q36753020-13B0FC97-2473-4348-9095-81D2A8AE702DQ39637667-4FDFA226-C6F3-4625-AFBC-529F43225FBDQ39834812-C99D7614-14B6-4370-98AF-2B564A102E4DQ39834941-5A482575-8C04-41F5-952F-03166236BD43Q39851512-9947A066-AC53-4A58-9974-26655E1511CCQ42602439-29EEB98B-D8EE-48E9-8301-1B2058AE61C8Q46602051-8ECCB4C4-1A80-4022-976F-0E4EE1FC542AQ54388935-4229BF71-056F-4DA4-8755-FE6543AA2C68
P2860
In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.
description
1986 nî lūn-bûn
@nan
1986年の論文
@ja
1986年論文
@yue
1986年論文
@zh-hant
1986年論文
@zh-hk
1986年論文
@zh-mo
1986年論文
@zh-tw
1986年论文
@wuu
1986年论文
@zh
1986年论文
@zh-cn
name
In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.
@ast
In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.
@en
type
label
In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.
@ast
In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.
@en
prefLabel
In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.
@ast
In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.
@en
P2093
P2860
P356
P1476
In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.
@en
P2093
P2860
P304
P356
10.1128/AAC.29.2.201
P407
P577
1986-02-01T00:00:00Z